Bristol-Myers Squibb Co (NYSE:BMY) reported Q3 adjusted EPS of $0.45, three cents better than the analyst consensus on Capital IQ. Revenue was $3.92 billion, ahead of expectations of $3.81 billion. "Our financial results in the third quarter reflect our continued focus on balancing long-term growth with short-term performance, as we achieved significant progress in our pipeline and saw strong in-market performance for key products including Eliquis, Yervoy, Sprycel and Orencia," said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb Co (NYSE:BMY).Bristol-Myers Squibb's global sales in the third quarter included Eliquis, which grew by $175 million, Yervoy, which grew 47%, Sprycel, which grew 22%, Orencia, which grew 18%, and Daklinza and Sunvepra, which had combined sales of $49 million. Bristol-Myers Squibb is adjusting its 2014 GAAP EPS guidance range to $1.15 - $1.25 from $1.50 - $1.60 and confirming its non-GAAP EPS guidance range of $1.70 - $1.80. Both GAAP and non-GAAP guidance assume current exchange rates and that the R&D tax credit will be extended by Congress in 2014. The Street view for non-GAAP earnings is $1.78 per share.Moody's Corporation (NYSE:MCO) reported Q3 earnings and revenue that topped the Street view. Moody's Corporation (NYSE:MCO) reported 3Q 2014 GAAP EPS up 20% from 3Q13 to $1.00 and non-GAAP EPS up 17% from 3Q 2013 to $0.97, topping the Street view of $0.90 per share. Revenue was $816.1 million for Q3 2014, up 16% from $705.5 million for Q3 2013 revenue, versus the $787 million the Street expected, according to Capital IQ estimates.Moody's maintained its fiscal 2014 earnings guidance of $3.95 to $4.05, versus a Street view of $4.03. Moody's declared a regular quarterly dividend of $0.28 per share of MCO Common Stock. The dividend will be payable on December 10, 2014 to stockholders of record at the close of business on November 20, 2014. MCO trades in a 52-week range of $66.91 to $96.50.IMS Health Holdings Inc (NYSE:IMS) reported Q3 earnings that were ahead of analysts' expectations but cut its guidance for sales growth due to the stronger U.S. dollar against foreign currencies. It also set its EPS guidance below the Street's view. The provider of information and technology services to the healthcare and life sciences industries said adjusted earnings fell to $0.37 per diluted share from $0.47 a year ago but was ahead of the $0.34 average estimate from analysts polled by Capital IQ. Revenue rose 5.4% to $656 million but missed the $668 million consensus.For FY2014, IMS Health Holdings Inc (NYSE:IMS) said it now expects revenue growth of 3.8% to 4.0%, down from the previous guidance of growth between 5% and 6%, and adjusted diluted EPS of $1.34 to $1.36, missing the $1.39 consensus. On a reported basis, IMS Health had a profit of $47 million or $0.14 per diluted share compared to a loss of $20 million or $0.07 the year earlier. IMS trades in a 52-week range between $21.63 and $28.48.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
